Advertisement

Topics

Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

2016-03-22 06:18:53 | BioPortfolio

Published on BioPortfolio: 2016-03-22T06:18:53-0400

Clinical Trials [8689 Associated Clinical Trials listed on BioPortfolio]

A Study of NBF-006 in Non-Small Cell Lung,Pancreatic, or Colorectal Cancer

This is an open-label, non-controlled study to investigate the safety, efficacy and pharmacokinetics (PK) of NBF-006 in patients with advanced non-small cell lung cancer (NSCLC), pancreati...

Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer

The main purpose of this study is to assess the safety, tolerability and anti-tumor activity of the experimental study drug pembrolizumab (also known as Keytruda or MK-3475) in people with...

Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Lung cancer is the leading cause of cancer mortality worldwide and in the U.K alone; there are 38,000 new cases of non-small cell lung cancer (NSCLC) a year. The new treatment being teste...

Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer

To compare the efficacy of AM0010 in combination with pembrolizumab versus pembrolizumab alone in patients with metastatic Non-Small Cell Lung Cancer as measured by objective response rate

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants with metas...

PubMed Articles [33430 Associated PubMed Articles listed on BioPortfolio]

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.

Preclinical and early clinical studies suggest that combining epigenetic agents with checkpoint inhibitors can potentially improve outcomes in patients with previously treated advanced non-small cell ...

Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer.

Anti-PD-1 immunotherapy has dramatically shifted therapeutic perspectives for advanced non-small cell lung cancer (NSCLC). We assessed cost-effectiveness of anti-PD-1 antibody pembrolizumab compared t...

Semimechanistically Based Modeling of Pembrolizumab Time Varying Clearance Using Four Longitudinal Covariates in Patients with Non-Small Cell Lung Cancer.

Time varying clearance has been recently recognized in FDA drug labels for oncology monoclonal antibodies (mAbs). Pembrolizumab population CL at steady-state decreased about 20% from the first dose, a...

The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer.

Currently, platinum-based chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) that is not driven by identifiable genetic events, such as sensitizing mutat...

Pembrolizumab for the first-line treatment of non-small cell lung cancer.

Platinum-based chemotherapy had long played a role as standard therapy for the first-line treatment of advanced or recurrent non-small cell lung cancer (NSCLC). However, immune checkpoint inhibitors s...

Medical and Biotech [MESH] Definitions

Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.

A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).

Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.

Tumor suppressor genes located in the 18q21-qter region of human chromosome 18. The absence of these genes is associated with the formation of colorectal cancer (DCC stands for deleted in colorectal cancer). The products of these genes show significant homology to neural cell adhesion molecules and other related cell surface glycoproteins.

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

More From BioPortfolio on "Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial